Evidence map›Paper›PMID 15987446›Full record

ArticleBreast cancer research : BCR2005

Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases.

Manabu Fujita, Natalya M Khazenzon, Shikha Bose, Kiyotoshi Sekiguchi, Takako Sasaki, William G Carter, Alexander V Ljubimov, Keith L Black, Julia Y Ljubimova

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.Journal of controlled release : official journal of the Controlled Release Society · 2013
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Manabu FujitaMaxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. fujitam@cshs.org
Natalya M Khazenzon
Shikha Bose
Kiyotoshi Sekiguchi
Takako Sasaki
William G Carter
Alexander V Ljubimov
Keith L Black
Julia Y Ljubimova
Cedars-Sinai Medical Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAMax Planck Society · DEProtein Research Foundation · JP

Funding

DEVELOPMENTAL STUDIES HYBRIDOMA BANKN01HD023144 · NICHD · JOHNS HOPKINS UNIVERSITY · PI AUGUST, J. THOMAS THOMAS · 1992 to 1996
–
NICHD NIH HHS N01-HD-2-3144
6 · The paper itself

Abstract

introductionLaminins are the major components of vascular and parenchymal basement membranes. We previously documented a switch in the expression of vascular laminins containing the alpha4 chain from predominantly laminin-9 (alpha4beta2gamma1) to predominantly laminin-8 (alpha4beta1gamma1) during progression of human brain gliomas to high-grade glioblastoma multiforme. Here, differential expression of laminins was studied in blood vessels and ductal epithelium of the breast.

methodIn the present study the expressions of laminin isoforms alpha1-alpha5, beta1-beta3, gamma1, and gamma2 were examined during progression of breast cancer. Forty-five clinical samples of breast tissues including normal breast, ductal carcinomas in situ, invasive ductal carcinomas, and their metastases to the brain were compared using Western blot analysis and immunohistochemistry for various chains of laminin, in particular laminin-8 and laminin-9.

resultsLaminin alpha4 chain was observed in vascular basement membranes of most studied tissues, with the highest expression in metastases. At the same time, the expression of laminin beta2 chain (a constituent of laminin-9) was mostly seen in normal breast and carcinomas in situ but not in invasive carcinomas or metastases. In contrast, laminin beta1 chain (a constituent of laminin-8) was typically found in vessel walls of carcinomas and their metastases but not in those of normal breast. The expression of laminin-8 increased in a progression-dependent manner. A similar change was observed from laminin-11 (alpha5beta2gamma1) to laminin-10 (alpha5beta1gamma1) during breast tumor progression. Additionally, laminin-2 (alpha2beta1gamma1) appeared in vascular basement membranes of invasive carcinomas and metastases. Chains of laminin-5 (alpha3beta3gamma2) were expressed in the ductal epithelium basement membranes of the breast and diminished with tumor progression.

conclusionThese results suggest that laminin-2, laminin-8, and laminin-10 are important components of tumor microvessels and may associate with breast tumor progression. Angiogenic switch from laminin-9 and laminin-11 to laminin-8 and laminin-10 first occurs in carcinomas in situ and becomes more pronounced with progression of carcinomas to the invasive stage. Similar to high-grade brain gliomas, the expression of laminin-8 (and laminin-10) in breast cancer tissue may be a predictive factor for tumor neovascularization and invasion.

Indexed as

Neovascularization, PathologicBasement MembraneBrain NeoplasmsBreast NeoplasmsCapillariesCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingDisease ProgressionFemaleGene Expression ProfilingHumansImmunohistochemistryLamininNeoplasm MetastasisProtein IsoformsLamininlaminin 10laminin 8laminin 9Protein Isoforms

Identifiers

PMID15987446
PMCPMC1175051
OpenAlexW1601529652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.